CrewCrew
FeedSignalsMy Subscriptions
Get Started
Bio tech company updates

Bio tech company updates — 11/21/2026

  1. Signals
  2. /
  3. Bio tech company updates

Bio tech company updates — 11/21/2026

Bio tech company updates|November 21, 2026(59m ago)1 min read8.4AI quality score — automatically evaluated based on accuracy, depth, and source quality
0 subscribers

This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.

AstraZeneca Korea and Seoul Biohub selected Molcube and BuildGene for a 2026 global open-innovation program, while Curocell’s Limkato CAR-T therapy received a negotiated insurance price ceiling. The two reports cover startup support and a pending coverage decision, respectively.

Key Findings

  • AstraZeneca Korea and Seoul Biohub selected Molcube and BuildGene for their 2026 Global Open Innovation program, which is intended to help Korean biotech and healthcare startups expand overseas.
  • Curocell’s CAR-T therapy Limkato received a negotiated insurance price ceiling of 280,016,050 won, reported as about $210,071 and roughly 22% below Kymriah’s price. Coverage still requires a final health policy committee vote.
en.sedaily.com

Korea


Details


AstraZeneca and Seoul Biohub select two startups

AstraZeneca Korea and Seoul Biohub chose Molcube and BuildGene for the 2026 Global Open Innovation program. The joint initiative is in its second year and aims to support Korean biotech and healthcare startups seeking to expand overseas.

Biotech innovation program coverage featuring Molcube and BuildGene
Biotech innovation program coverage featuring Molcube and BuildGene

koreabiomed.com

AstraZeneca and Seoul Biohub pick Molcube and BuildGene for global R&D program < Pharma < Article -

en.sedaily.com

Korea


Limkato receives negotiated price ceiling

Curocell’s Limkato received a negotiated insurance price ceiling of 280,016,050 won (about $210,071), approximately 22% below Kymriah, according to the report. A final health policy committee vote is still needed for coverage, which the report says is planned for December 1.

Laboratory setting illustrating CAR-T therapy coverage
Laboratory setting illustrating CAR-T therapy coverage

techtimes.com

techtimes.com


Sources

koreabiomed.com

AstraZeneca and Seoul Biohub pick Molcube and BuildGene for global R&D program < Pharma < Article -

techtimes.com

techtimes.com

This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.

Explore related topics
  • QWhat support do Molcube and BuildGene receive?
  • QWhen will Limkato's final coverage vote occur?
  • QWhat are Molcube and BuildGene's core technologies?

Powered by

CrewCrew

Sources

Want your own AI intelligence feed?

Create custom signals on any topic. AI curates and delivers 24/7.